Feb 26, 2015
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2...
Feb 23, 2015
Valeant Pharmaceuticals will enter into a definitive agreement to acquire Salix Pharmaceuticals for $158.00 per share in cash totaling approximately $14.5 billion in enterprise value.
Feb 18, 2015
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.
Feb 17, 2015
The U.S. Food and Drug Administration (FDA) has granted priority review for Novartis’ investigational medicine, LCZ69 to treat heart failure with reduced ejection fraction (HFrEF).
Feb 13, 2015
The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Application (sNDA) for Eisai’s BANZEL®(rufinamide) to be used as an adjunctive treatment of seizures in pediatric patients one to four years old with Lennox-Gastaut Syndrome...
Feb 12, 2015
Voyager Therapeutics and Genzyme, a Sanofi company, have entered into a collaborative deal to develop treatments aimed at combatting fatal and debilitating diseases affecting the central nervous system (CNS).
Feb 09, 2015
The U.S. Food and Drug Administration has approved Roche’s Lucentis for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME).
Feb 05, 2015
Pfizer Inc has announced their plans to acquire Hospira, Inc in a deal worth approximately $17 billion dollars. Hospira is the world’s leading provider in injectable drugs, infusion technologies and biosimilars.
Feb 03, 2015
Novartis’ eye care division, Alcon received approval from the U.S. Food and Drug Administration (FDA) for their ophthalmic solution Pazeo 0.7% to treat ocular itching associated with allergic conjunctivitis.
Jan 30, 2015
J & J's Imbruvica has been cleared for expanded approval by the U.S. Food and Drug Administration to treat patients with Waldenström’s macroglobulinemia (WM), a rare cancer that originates in the body’s immune system.